HS
AZN icon

HighVista Strategies’s AstraZeneca AZN Stock Holding History

HighVista Strategies’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,650
Closed -$1.66M – 223
2017
Q1 		$1.66M Buy
+26,650
New +$1.55M 0.37% 61
2014
Q1 		– Sell
-43,337
Closed -$2.57M – 149
2013
Q4 		$2.57M Buy
+43,337
New +$2.35M 0.46% 47

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

HighVista Strategies's AZN Position: Q2 2017 in Review

HighVista Strategies sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 26,650 shares — an estimated $1.66M sold.

HighVista Strategies first reported a position in AZN in Q4 2013 and held it in 2 quarters. The position peaked at $2.57M in Q4 2013. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

  • HighVista Strategies reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
  • HighVista Strategies sold 26,650 AstraZeneca shares in Q2 2017, an estimated $1.66M.
  • HighVista Strategies first reported a position in AstraZeneca in Q4 2013 and held it in 2 quarters.
  • HighVista Strategies's AstraZeneca position peaked at $2.57M in Q4 2013.
  • 466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on HighVista Strategies's 13F filing for Q2 2017, filed 14 Aug 2017.